A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Key claim: A first-in-human Phase 1 study is evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of STX-0712 in patients with advanced CMML or AML who have exhausted standard treatment options.
Abstract
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.
Why this matters
CMML patients who progress after hypomethylating agents have few options and historically poor outcomes, so any first-in-human agent specifically enrolling advanced CMML expands the otherwise narrow late-line pipeline for this MDS/MPN overlap subtype. Co-enrollment with AML reflects the shared myeloid biology and transformation risk that frames CMML’s natural history. Tracking STX-0712’s early signals will help determine whether a novel mechanism can address the unmet need in refractory CMML.